The hematopoietic growth factors (HGFs) such as granulocyte colony-stimulating factor (G-CSF) filgrastim and pegfilgrastim and the granulocyte-macrophage colony-stimulating factor (GM-CSF) sargramostim have currently been approved by the US Food and Drug Administration to mitigate hematopoietic abnormalities in ARS in order to improve patients survival [9]. This evidence concerns the gene CSF2 and Axenfeld-Rieger syndrome.